8-K: Supernus Reports Record Q4, Full Year 2025 Results

Supernus Pharmaceuticals announced record total revenues for the fourth quarter and full year 2025, driven by strong growth in its key products and strategic acquisitions.

Summary

• Supernus Pharmaceuticals achieved record total revenues of $211.6 million for the fourth quarter ended December 31, 2025, marking a 21% increase compared to the same period last year.
• Full year 2025 total revenues also reached a record $719.0 million, an increase of 9% over the prior year.
• Combined revenues from the company's four growth products (Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO) grew by 45% to $161.3 million in Q4 2025 and by 40% to $521.8 million for the full year 2025.
• The company reported a GAAP operating loss of $4.0 million for Q4 2025 and $62.3 million for FY 2025, primarily due to higher selling, general and administrative expenses, including $72.9 million in acquisition-related costs for the Sage acquisition.
• GAAP net loss was $4.1 million ($0.07 diluted loss per share) for Q4 2025 and $38.6 million ($0.68 diluted loss per share) for FY 2025.
• Cash, cash equivalents, and current marketable securities stood at $308.7 million as of December 31, 2025, a decrease from $453.6 million at December 31, 2024, mainly due to funding the Sage acquisition.
• New patient initiation for ONAPGO resumed in the first quarter of 2026 following efforts to secure additional product supply.
• Full year 2026 financial guidance projects total revenues between $840 million and $870 million, operating earnings between $0 million and $30 million, and adjusted operating earnings (Non-GAAP) between $140 million and $170 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While the company achieved record revenues and strong growth in its strategic products, the significant GAAP operating and net losses, primarily due to acquisition costs, temper the overall positive sentiment. The resumption of ONAPGO patient initiation is a positive, but the cash burn for the acquisition is notable.

Positives

• Achieved record total revenues of $211.6 million in Q4 2025 (+21% year-over-year) and $719.0 million for FY 2025 (+9% year-over-year).
• Combined revenues of the four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) increased significantly by 45% in Q4 2025 to $161.3 million and 40% in FY 2025 to $521.8 million.
• Net sales of Qelbree increased 9% to $81.0 million in Q4 2025 and 26% to $304.7 million for FY 2025, driven by volume growth.
• Net sales of GOCOVRI increased 5% to $38.6 million in Q4 2025 and 12% to $146.8 million for FY 2025.
• Collaboration revenue from ZURZUVAE was $32.8 million in Q4 2025 and $53.0 million for FY 2025, with U.S. sales increasing approximately 187% in Q4 2025 compared to Q4 2024.
• ONAPGO generated $8.9 million in net product sales in Q4 2025 and $17.3 million for FY 2025 following its U.S. commercial launch in April 2025.
• New patient initiation for ONAPGO resumed in Q1 2026 due to securing additional product supply.
• Successfully completed the acquisition of Sage Therapeutics, Inc. and received U.S. FDA approval and launched ONAPGO in 2025.
• Recognized $15.0 million in licensing revenue in Q4 2025 related to a regulatory milestone under the collaboration agreement with Shionogi.
• Royalty, licensing and other revenues increased 165% in Q4 2025 and 63% in FY 2025.

Negatives

• Reported a GAAP operating loss of $4.0 million in Q4 2025 and $62.3 million for FY 2025, a significant decline from operating earnings in the prior year periods.
• Incurred a GAAP net loss of $4.1 million in Q4 2025 and $38.6 million for FY 2025, compared to net earnings in the prior year periods.
• Diluted loss per share was $0.07 in Q4 2025 and $0.68 for FY 2025, contrasting with diluted earnings per share in the prior year.
• Cash, cash equivalents, and current marketable securities decreased to $308.7 million as of December 31, 2025, from $453.6 million as of December 31, 2024, primarily due to funding the Sage acquisition.
• Selling, general and administrative expenses increased substantially, including approximately $72.9 million of acquisition-related costs associated with the Sage acquisition in 2025.
• Net product sales of older products like APOKYN, Trokendi XR, and Oxtellar XR experienced significant declines due to generic competition, with Oxtellar XR sales down 59% for FY 2025.
• Increased contingent consideration loss and incremental intangible asset amortization expense for ZURZUVAE and ONAPGO contributed to higher costs.

Risks

• Ability to sustain and increase profitability.
• Ability to raise sufficient capital to fully implement corporate strategy.
• Ability to increase the number of prescriptions and net revenue for its products and those of its subsidiaries.
• Ability to commercialize its products and those of its subsidiaries.
• Ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies.
• Risks related to product research and development activities, including the timing and progress of clinical trials and projected expenditures.
• Ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize product candidates.
• Ability to protect intellectual property and operate its business without infringing upon the intellectual property rights of others.
• Expectations regarding federal, state, and foreign regulatory requirements.
• Therapeutic benefits, effectiveness, and safety of product candidates.
• Accuracy of estimates of the size and characteristics of the markets that may be addressed by its product candidates.
• Ability to increase manufacturing capabilities for its products and product candidates.
• Projected markets and growth in markets.
• Product formulations and patient needs and potential funding sources.
• Staffing needs.
• Changes to laws and regulations applicable to the industry.
• Impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs.
• Other risk factors set forth in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other SEC filings.

Future Outlook

Supernus Pharmaceuticals projects full year 2026 total revenues to be between $840 million and $870 million. Operating earnings are expected to range from $0 million to $30 million, with adjusted operating earnings (Non-GAAP) anticipated between $140 million and $170 million. The company expects ONAPGO net sales to be $45 million to $70 million and Trokendi XR and Oxtellar XR net sales to be $40 million to $50 million in 2026. The company also plans to initiate a Phase 1 study for SPN-443 in the second half of 2026 and expects a second ONAPGO supplier in 2027.

Management Comments

• "We made significant progress in 2025 against our strategic objectives, with record total revenues, including strong growth in combined revenues of our growth products, the successful acquisition of Sage Therapeutics, Inc., and the U.S. Food and Drug Administration's approval and launch of ONAPGO for Parkinson's disease." Jack Khattar, President and CEO.
• "In 2026, we are focused on continued progress of our key growth products, including resumption of new patient initiation for ONAPGO, while advancing our pipeline of promising therapeutic candidates." Jack Khattar, President and CEO.

Industry Context

StockSavvy.ai notes that Supernus Pharmaceuticals is strategically navigating the CNS disease market by focusing on growth products like Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO, while managing the decline of older products facing generic competition. The successful integration of Sage Therapeutics and the launch of ONAPGO position Supernus to capture market share in key neurological and psychiatric segments, aligning with broader industry trends of specialized CNS therapies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for long-term growth from new products and acquisitions, but short-term profitability challenges due to acquisition costs and declining legacy products. Diluted loss per share in 2025.
• Customers (Patients/Prescribers): Resumption of ONAPGO patient initiation is positive, ensuring access to treatment. Continued availability of a diverse CNS portfolio.
• Employees: Successful acquisition of Sage Therapeutics implies integration efforts and potential for expanded roles or restructuring.
• Suppliers: Company is actively working with current and new suppliers for ONAPGO, indicating ongoing business relationships and potential for new partnerships.

Next Steps

• Continue progress of key growth products in 2026.
• Advance the pipeline of promising therapeutic candidates.
• Initiate a Phase 1 single-ascending/multiple-ascending dose study for SPN-443 in adult healthy volunteers in the second half of 2026.
• Work with a second supplier for ONAPGO, which is expected to begin supplying in 2027.

Key Dates

Recommendation

The company demonstrates strong top-line growth in its strategic products and successful execution of its acquisition strategy, which are positive long-term indicators. However, the substantial GAAP operating and net losses, driven by acquisition-related expenses and the decline of legacy products, introduce short-to-medium term profitability concerns. The decrease in cash reserves due to the acquisition also warrants caution. Investors should hold to observe how the company integrates its acquisitions, manages expenses, and translates revenue growth into sustainable GAAP profitability in 2026 and beyond, especially given the relatively low operating earnings guidance for 2026.

Keywords

Supernus, Pharmaceuticals, CNS diseases, Qelbree, GOCOVRI, ONAPGO, ZURZUVAE, ADHD, Parkinson's disease, Postpartum depression, Epilepsy, Financial results, Earnings, Biopharmaceutical, SEC filing, 8-K, Revenue, Operating earnings, Pipeline, Clinical trials, Sage acquisition